Responses
Short Oral Presentation
Short oral presentation session 5: lupus nephritis
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
Compose a Response to This Article
Other responses
No responses have been published for this article.